--- title: "Galapagos Shareholders Approve Name Change to Lakefront Biotherapeutics and Broad Governance Overhaul" type: "News" locale: "en" url: "https://longbridge.com/en/news/284587561.md" description: "Galapagos NV shareholders approved a name change to Lakefront Biotherapeutics and a governance overhaul during their meetings on April 28, 2026. Key changes include the appointment of CEO Henry Gosebruch as executive director, new independent directors, and a renewed focus on sustainability reporting. The board was authorized to repurchase shares and increase capital by 20%. The company aims to support its transformation and growth phase, with Gino Santini as the new chair. Current analyst rating for GLPG stock is a Hold with a price target of $28.00." datetime: "2026-04-29T13:38:27.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284587561.md) - [en](https://longbridge.com/en/news/284587561.md) - [zh-HK](https://longbridge.com/zh-HK/news/284587561.md) --- # Galapagos Shareholders Approve Name Change to Lakefront Biotherapeutics and Broad Governance Overhaul ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Galapagos ( (GLPG) ) has provided an announcement. On 28 April 2026, Galapagos NV held its Annual and Extraordinary Shareholders’ Meetings, where investors approved the 2025 annual and remuneration reports, discharged directors and the auditor from liability, and confirmed a broad refresh of the board with the appointment of CEO Henry Gosebruch as executive director and several new independent and non-executive directors. Shareholders also reappointed the statutory auditor and mandated it to provide assurance on the company’s CSRD sustainability reporting, underlining an increased focus on governance and non-financial disclosure. At the Extraordinary Meeting the company’s owners backed a name change to “Lakefront Biotherapeutics,” effective 8 May 2026, authorized the board to repurchase shares, and renewed authorized capital by up to 20% of existing share capital, giving management more financial and strategic flexibility. The governance overhaul and new capital tools are intended to support Galapagos’ ongoing transformation and next growth phase, with incoming chair Gino Santini expected to play a key role in executing the strategy and balancing patient impact with sustainable shareholder returns. The most recent analyst rating on (GLPG) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page. **Spark’s Take on GLPG Stock** According to Spark, TipRanks’ AI Analyst, GLPG is a Neutral. GLPG scores strongest on financial positioning (very low leverage and large cash resources) and supported valuation (low P/E). The main offset is persistent negative operating/free cash flow and earnings quality concerns highlighted by non-recurring profit drivers and ongoing restructuring/wind-down cash needs; technical signals are broadly neutral. To see Spark’s full report on GLPG stock, click here. **More about Galapagos** Galapagos NV, soon to be renamed Lakefront Biotherapeutics, is a Belgium-based biotechnology company focused on developing meaningful medicines for patients with serious diseases in areas of high unmet need. Leveraging a modality-agnostic asset selection strategy and strong deal-making capabilities, it prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept to create value for patients and shareholders. **Average Trading Volume:** 144,100 **Technical Sentiment Signal:** Strong Sell **Current Market Cap:** $1.89B Learn more about GLPG stock on TipRanks’ Stock Analysis page. ### Related Stocks - [GLPG.US](https://longbridge.com/en/quote/GLPG.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [LKFT.US](https://longbridge.com/en/quote/LKFT.US.md) ## Related News & Research - [08:00 ETAvance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership](https://longbridge.com/en/news/286094661.md) - [FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars](https://longbridge.com/en/news/285969539.md) - [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md) - [BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches](https://longbridge.com/en/news/286199057.md) - [Pliant Therapeutics Q1 net loss narrows on lower expenses](https://longbridge.com/en/news/285998196.md)